Current management of melanoma

Dunki-Jacobs, Erik M.; Callender, Glenda G.; McMasters, Kelly M.

doi:10.1067/j.cpsurg.2013.04.001

Cited by 42 publications

(34 citation statements)

References 158 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taken together, these data suggested that prophylactic immunization with MCMV-gp100KGP strongly protected mice from highly metastatic B16-F10 melanoma. If melanoma is detected early, the long-term prognosis is very promising; however, treating metastatic melanoma is difficult, and the prognosis of patients with metastatic melanoma is extremely poor, with a median survival duration of about 7 months (38). Thus, we next evaluated the efficacy of the MCMV-gp100KGP vector in a therapeutic setting, in which the metastatic melanoma was already established in the lung.…”

Section: Construction and Characterization Of Recombinant Mcmv-gp100 mentioning

confidence: 99%

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma

Qiu

Huang

Grenier

et al. 2015

Cancer Immunology Research

View full text Add to dashboard Cite

The presence of tumor-infiltrating CD8 þ T cells is associated with tumor regression and better prognosis. Cytomegalovirus (CMV) infection elicits a robust and long-lasting CD8 þ T-cell response, which makes CMV a potentially promising vaccine vector against cancer. In the current study, we used recombinant murine CMV (MCMV) strains as prophylactic and therapeutic vaccines in an aggressive B16 lung metastatic melanoma model. Immunization with MCMV-expressing ovalbumin (OVA) induced a potent OVA-specific CD8 þ T-cell response and was effective in protecting mice from OVAexpressing B16 melanoma in an antigen-dependent manner. We engineered MCMV to express a modified B16 melanoma antigen gp100 (MCMV-gp100KGP). Immunization with MCMV-gp100KGP was highly effective in overcoming immune tolerance to self-antigen and induced a strong, long-lasting gp100-specific CD8 þ T-cell response even in the presence of preexisting anti-CMV immunity. Furthermore, both prophylactic and therapeutic vaccinations of mice with MCMV-gp100KGP effectively protected mice from highly aggressive lung B16-F10 melanoma, and the protection was mediated by gp100-specific CD8 þ T cells. We showed that MCMV is a superior vaccine vector compared with a commonly used vesicular stomatitis virus vector. Collectively, our studies demonstrate that CMV is a promising vaccine vector to prevent and treat tumors.

show abstract

Section: Construction and Characterization Of Recombinant Mcmv-gp100 mentioning

confidence: 99%

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma

Qiu

Huang

Grenier

et al. 2015

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…Melanoma is the most aggressive form of skin cancer, and its incidence is increasing at a rate greater than any other form of cancer; further, it remains one of the most difficult cancers to treat [1]. Therefore, the development of effective therapy or at least as adjuvant of classical chemotherapy is still required.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin

Beninati¹,

Oliverio²,

Cordella³

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

a b s t r a c tIn this study, we have evaluated the potential antineoplastic effects of a-mangostin (a-M), the most representative xanthone in Garcinia mangostana pericarp, on melanoma cell lines. This xanthone markedly inhibits the proliferation of high-metastatic B16-F10 melanoma cells. Furthermore, by deeply analyzing which steps in the metastatic process are influenced by xanthone it was observed that a-M strongly interferes with homotypic aggregation, adhesion, plasticity and invasion ability of B16-F10 cells, probably by the observed reduction of metalloproteinase-9 activity. The antiproliferative and antimetastatic properties of a-M have been established in human SK-MEL-28 and A375 melanoma cells. In order to identify pathways potentially involved in the antineoplastic properties of a-M, a comparative mass spectrometry proteomic approach was employed. These findings may improve our understanding of the molecular mechanisms underlying the anti-cancer effects of a-M on melanoma.

show abstract

“…Snow'un bu makalesi ELND ile ilgili neredeyse yüz yıl sürecek tartışmayı da beraberinde getirmiştir. Ancak günümüze kadar yapılan randomize kontrollü çalışmalar ELND'nin sağkalım üzerine bir kazancı olduğunu gösterememişlerdir (3,11,12 Kalın MM'li (Breslow kalınlığı >4 mm) hastaların sistemik metastaz riski arttığı için SLNB'den fayda görmeyeceklerine dair bir yaklaşım gelişmiş olsa da yapılan çalışmalar, kalın MM'si olup SLNB'si negatif olan hastaların pozitif olanlara göre prognozunun daha iyi olduğunu göstermiştir. Bu nedenle kalın MM'li hastalara da SLNB önerilebilir (22).…”

Section: Elektif Lenf Nodu Diseksiyonu (Elnd) Ve Sentinel Lenf Nodu (unclassified

“…Cerrahi olarak ise cilt ve ciltaltı dokular geçildikten sonra hem maviye boyanmış lenfatik kanallar izlenerek hem de elle kontrol edilen gama prob kullanılarak SLN tespit edilir, çevre dokulardan serbestleştirilerek çıkarılır. O lenfatik ağdaki en radyoaktif lenf nodu (radyoaktivitesi diğer lenf nodlarından en az %10 fazla), maviye boyanan lenf nodu veya klinik olarak ele gelen lenf nodu SLN olarak tanımlanır (1,3,26). Tüm SLN'ler histopatolojik ve S-100 ve HMB-45 gibi boyalarla immünhistokimyasal değerlendirme için patoloji birimine gönderilmelidir.…”

Section: Slnb Teknik Detaylarıunclassified

See 1 more Smart Citation

Sentinel Lymph Node Biopsy in Malignant Melanoma: Current Approaches

Uzun¹,

Bitik²

2014

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETSentinel lenf nodu biyopsisi (SLNB), malign melanomlu hastaların lenf nodlarının durumunu belirlemek için kullanılan bir evreleme prosedürüdür. Elektif lenf nodu diseksiyonuna göre çok daha az komplikasyon riski bulunmaktadır. SLNB, Breslow kalınlığı <0.75 mm. olan hastalara önerilmemektedir. Teknesyum sülfür kolloid ve vital mavi boyanın birlikte kullanılması ile yapılan lenfatik haritalama sonucu sentinel lenf nodu %99 oranında tespit edilebilir. SLNB, klinik olarak lenf nodu metastazı olmayan malign melanomlu hastalarda en önemli prognostik faktördür. SLNB'de mikrometastaz tespit edilmesi, tamamlayıcı lenf nodu diseksiyonu endikasyonudur. Bu derlemede SLNB hakkında hem güncel literatür bilgisi hem de süregelen tartışmalar ele alınmıştır. Anahtar Kelimeler: malign melanom, sentinel lenf nodu, lenfosintigrafi. ABSTRACT Sentinel lymph node biopsy (SLNB) is a staging procedure used to determine the nodal status of patients with melanoma. It has a significantly lower complication rate compared with elective lymph node dissection. SLNB is not recommended for very thin lesions (Breslow thickness ≤ 0.75 mm). The combined lymphatic mapping technique of technetium sulfur colloid with vital blue dye would result in identification of the sentinel node in 99% of patients when performed correctly. SLNB is the single most important prognostic factor in melanoma patients without clinical evidence of nodal metastasis Currently, micrometastatic disease found on SLNB is an indication for completion lymph node dissection. In this review, both current literature and ongoing debates considering SLNB are discussed.

show abstract

Current management of melanoma

Cited by 42 publications

References 158 publications

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma

Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin

Sentinel Lymph Node Biopsy in Malignant Melanoma: Current Approaches

Contact Info

Product

Resources

About